Altimmune, a drug company based in Gaithersburg, has agreements with investors to raise about $14.7 million, excluding fees and expenses, in a second round of financing. The company plans to sell 15,565 shares of convertible preferred stock and warrants to new and existing investors in a round that the company expects to close around Aug. 21.